Molecular genetics diagnostic company Mainz Biomed has entered a commercial partnership with TESTDNA for its ColoAlert test in Poland.

Mainz Biomed offers ColoAlert as an at-home detection test for colorectal cancer (CRC) and both companies will work together in the coming weeks to plan and roll out co-marketing activities to fully commercialise the test in the Polish market.

Mainz Biomed chief commercial officer Darin Leigh said: “Entering the Polish market is an important milestone for the company and we are thrilled by the opportunity to partner with TESTDNA to establish ColoAlert’s commercial footprint in this territory.

“TESTDNA is an exciting addition to our growing network of international laboratory partners who are committed to providing cutting-edge diagnostic screening tools to improve patient survival and disease prevention from deadly indications such as CRC, the second most lethal cancer in Europe.”

ColoAlert is a non-invasive test that is expected to facilitate better early identification of CRC than faecal occult blood tests.

The test leverages polymerase chain reaction technology to identify more cases of colorectal cancer than other stool tests.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This test is commercially marketed in select EU countries via corporate health programmes, direct sales and independent laboratories.

Furthermore, the test will be assessed in the company’s US pivotal study, called ReconAAsense.